obesity tirzepatide Effect of on Body Weight and Diabetes Control in Adults With Type 1 Diabetes and Overweight or Tirzepatide (ZEPBOUND) Approved for Chronic

have been prescribed a glucagonlike peptide1 drug for one or multiple indications, but 54% of users report affordability challenges.

- -, like orforglipron, promising easier global access

More than appetite support

/PRNewswire/ -- Today, Novo Nordisk announced that the U.S

PALO ALTO, Calif., September 28, 2023 (BUSINESS WIRE)-- Digbi Health, the leader in precision biology-based telehealth care for three of the top four healthcare costs - Obesity, T2D, and Digestive Health - announced today the launch of its latest innovation in obesity care,Digbi GLP-Fit, a scientifically-backed approach to identify the best treatment path for an individual to prevent and treat obesity. Key Highlights: Digbi GLP-Fituses the science of precision biology to identify the best treatment path for obesity for an individual with 87% accuracy, which may include 1) only precision nutrition, 2) a combination of precision nutrition and lower-cost drugs like Metformin, or 3) a combination of precision nutrition and GLP-1 medications